No difference between the groups was found regarding the clinical features, including age, sex, diagnosed tumor type, ECOG PS score, differentiation, number of metastatic sites, location of metastatic sites, KRAS mutation, or history of bevacizumab (all P>0.05) (Table 1). The gene discussed is KRAS; the disease is neoplasm.